AKT1 and esophageal cancer: These results suggest that KRT17 may affect tumour growth through Akt/EMT signaling pathway and a biomarker for the diagnosis and prognosis of ESCC, which provides evidence for guiding the treatment of esophageal cancer patients (Liu et al., 2020).